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Abstract To understand the structure-function relationship of
hepatocyte growth factor (HGF) in more detail, we analyzed one
of the other forms of HGF, deleted variant of HGF (dHGF), by
alanine scanning mutagenesis. We show here that there are at
least four sites important for dHGF to stimulate DNA synthesis
in cultured adult rat hepatocytes, and that the residues of HGF
essential for exerting its biological activity are not identical to
those of dHGF. In addition, two mutants showed a decrease
(approximately three-fold) in EC50 compared with wild-type
dHGF in an assay of mitogenic activity on rat hepatocytes.
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1. Introduction
Hepatocyte growth factor (HGF) is a heparin binding basic
protein initially identi¢ed as a potent mitogen for hepatocytes
[1^3]. The molecular cloning of HGF cDNA has predicted its
primary and tertiary structures [4,5]. Subsequently, both scat-
ter factor and ¢broblast-derived tumor cytotoxic factor were
found to be identical to HGF [6^10].
Recent studies have revealed that HGF is biologically mul-
tifunctional. It is a mitogen not only for hepatocytes but also
for various epithelial cells [11^14] and endothelial cells [9,13^
15], whereas it suppresses the growth of tumor cells
[7,9,13,14]. HGF executes these activities through its receptor,
the c-met proto-oncogene product [13,14,16^18].
HGF is a disul¢de-linked heterodimer composed of an K
chain with a molecular mass of 52^56 kDa and a L chain of
30^34 kDa [19,20]. HGF consists of six major domains: the
N-terminal domain (including the hairpin loop) and four krin-
gle domains in the K chain, and a serine protease-like domain
in the L chain [4,5].
A naturally occurring HGF variant (deleted variant of hep-
atocyte growth factor, dHGF) that arises from an alterna-
tively spliced transcript and lacks ¢ve amino acids (Phe-Leu-
Pro-Ser-Ser) in the ¢rst kringle domain was also found in
many cells or cell lines [10,21]. It has been reported that
dHGF is distinguishable from HGF in biological activity
and tertiary structure [10,22,23].
Numerous HGF mutants have been prepared in investiga-
tions of the HGF structure-function relationship [22,24^28].
Through these studies, it has been established that the N-ter-
minal domain and the ¢rst and second kringle domains are
required for its biological functions [22,24^26]. The impor-
tance of the ¢rst two domains has been demonstrated by
the ¢nding that a variant consisting of the N-terminal domain
and the ¢rst kringle domain binds to the receptor and has a
low level of scatter activity [27]. More recently, a series of
point mutations were systematically introduced into the ¢rst
two domains of HGF to identify the residues essential for the
mitogenic activity on rat hepatocytes [28]. Of more than
50 HGF mutants constructed in many laboratories, no mu-
tant has been found to have speci¢c activity signi¢cantly high-
er (two-fold or more) than that of HGF.
Since no structure-function study has been carried out with
dHGF, we conducted a mutational analysis of dHGF. To
analyze the role of the residues in the two N-terminal do-
mains, alanine scanning mutagenesis was employed [29]. We
describe here the identi¢cation of the residues of dHGF re-
quired for stimulating DNA synthesis in hepatocytes. We also
show that these residues are not identical to those of HGF. In
addition, two mutants showed a decrease in EC50 (dose re-
quired for half-maximal cell proliferative response) in an assay
of mitogenic activity on rat hepatocytes. The two dHGF mu-
tants are, therefore, the most potent mitogen for hepatocytes
among the HGF and dHGF variants constructed to date.
2. Materials and methods
2.1. Cells
Adult rat hepatocytes were prepared by the method of Seglen [30].
NFS-60 cells (murine myeloblastic cells) were kindly provided by Dr.
T. Suda (Kumamoto University, Japan). OK cells (American opos-
sum kidney epithelial cells) and Chinese hamster ovary (CHO) cells
were purchased from American Type Culture Collection (ATCC).
2.2. Construction of expression vectors for dHGF and its mutants
The plasmid to express human dHGF, designated pSRKTCF, was
constructed as follows. An SR K promoter-based vector termed
pcDL-SR K 296 [31] (a gift from Dr. Y. Takebe) was digested with
restriction enzymes PstI and KpnI, and the ends were blunted using
DNA blunting kit (Takara Shuzo). dHGF cDNA fragment was ex-
cised from pUCTCF, a plasmid with the entire coding sequence for
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human dHGF inserted between the BamHI and SphI sites of pUC 18
(Takara Shuzo), by digesting with BamHI and SphI. The fragment
was then treated with the DNA blunting kit, and inserted into the
blunt-ended pcDL-SR K296 vector. Site-directed mutagenesis was car-
ried out by a recombinant polymerase chain reaction (PCR) technique
as described by Higuchi [32]. pUCTCF was used as a template for the
PCRs. A BstPI/EcoRV fragment of pSRKTCF, which encodes the N-
terminal region and the ¢rst kringle domain, was replaced with the
BstPI/EcoRV fragment derived from each PCR product to generate
the various vectors to express dHGF mutants. CHO cells were trans-
fected with a mixture of 200 Wg of each expression plasmid and 10 Wg
of pSV2bsr, an expression vector for blasticidin S resistant gene (Fu-
nakoshi), by electroporation, and cultured in Iscove’s modi¢ed Dul-
becco’s medium (IMDM) supplemented with 10% FBS at 37‡C. After
3 days of incubation, the cells suspended in IMDM containing 10%
FBS and 5 Wg/ml of blasticidin S (Funakoshi) were seeded at an initial
density of 104 cells/200 Wl/well in 96-well plates. Two weeks after the
inoculation, the amount of mutant dHGF in the cultured medium in
each well was measured by an ELISA as previously described [33],
and the clones which expressed mutant proteins were selected.
2.3. Nomenclature of mutants
The mutations or mutants are de¢ned by the following, in the order
shown: (a) residue(s) to be replaced, (b) the position of the replaced
amino acid or the ¢rst residues of the mutated sequences in the amino
acid sequence, and (c) the residue or the sequence generated by the
mutagenesis (e.g. R42A or KIKTKK27AIATAA). The position of
each mutation is described by indicating the residue number of the
¢rst residue of the cluster in the amino acid sequence and the original
sequence (e.g. 42R or 27KIKTKK). Amino acid residues are num-
bered starting at the amino-terminus of the mature protein. The de-
duced amino acid sequences of HGF and dHGF together with the
positions of the mutations in dHGF mutants are shown in Fig. 1.
2.4. Heparin Sepharose chromatography
The a⁄nity of wild-type and dHGF mutants for heparin was de-
termined by FPLC on a HiTrap heparin column (Pharmacia). Con-
ditioned medium containing each dHGF mutant was applied to the
column (1 ml) equilibrated with 20 mM Tris-HCl (pH 7.5)-0.01%
Tween 80 (Sigma). The protein was eluted with a 45 min linear gra-
dient of 0^1.5 M NaCl in the bu¡er at a £ow rate of 0.5 ml/min, and
fractions (0.5 ml) were collected. The concentration of the dHGF
mutant in each fraction was determined by an ELISA employing a
rabbit anti-dHGF polyclonal antibody.
2.5. Puri¢cation
CHO cells producing dHGF mutants were cultured in IMDM with
5% calf serum at 37‡C for 1 week. Each mutant in the conditioned
medium was puri¢ed as previously described [23] with the following
modi¢cation. The conditioned medium was applied to an S-Sepharose
column (25U80 mm, Pharmacia) at a £ow rate of 4 ml/min. The
column was washed with an equilibration bu¡er (10 mM Tris-HCl,
pH 7.5, containing 0.3 M NaCl and 0.01% Tween 20) and then eluted
with the bu¡er containing 2 M NaCl. The fractions containing the
mutant were pooled and dialyzed against 10 mM phosphate bu¡er
(pH 7.0) containing 0.15 M NaCl and 0.01% Tween 80. The mutants
were further puri¢ed to homogeneity by the combination of Mono S
(Pharmacia) and heparin-5PW FPLC (Tosoh) as previously described
[23]. The protein concentration was determined by the method of
Lowry using bovine serum albumin as a standard protein.
2.6. Biological assays
Adult rat hepatocytes suspended in William’s E medium containing
10% FBS and 10 mM dexamethasone were seeded at an initial cell
density of 104 cells/100 Wl/well in 96-well plates. The cells were incu-
bated for 24 h at 37‡C. dHGF and dHGF mutants were partially
puri¢ed with heparin Sepharose, resuspended in phosphate-bu¡ered
saline (PBS) containing 0.01% Tween 80 and concentrated with Cen-
tricut (Kurabo). Each dHGF mutant was serially diluted with the
medium and added to each well. The plates were incubated for 22 h
at 37‡C. Subsequently, 1 WCi/10 Wl of [methyl-3H]thymidine (85 Ci/
mmol, Amersham) was added to each well and the plates were further
incubated for 2 h. The cells were washed with PBS and then trypsi-
nized. The radioactivity in the wells was measured using a Direct Beta
Counter, Matrix 96 (Packard). OK cells were maintained in DMEM
containing 10% FBS. The cells suspended in the medium were seeded
at a cell density of 104 cells/100 Wl/well and were incubated at 37‡C for
24 h. The medium was replaced with 100 Wl of fresh serum-free
DMEM and the cells were further incubated for 48 h. Subsequently,
the medium was replaced with 50 Wl of fresh serum-free DMEM, and
then serially diluted dHGF or each mutant in the serum-free medium
containing 0.1% bovine serum albumin was added to each well of the
plates (50 Wl/well). After the incubation at 37‡C for 22 h, 1 WCi/10 Wl
of [methyl-3H]thymidine (5 Ci/nmol, Amersham) was added to each
well and the plates were further incubated for 2 h. The cells were
washed with PBS and trypsinized. The radioactivity incorporated
into the cells was determined using Matrix 96. NFS-60 cells were
maintained in RPMI 1640 (Life Technologies) containing 10% FBS
and 10% conditioned medium of WEHI-3 cells. The cells suspended in
RPMI 1640 with 10% FBS were seeded at a cell density of 104 cells/50
Wl/well. Serially diluted dHGF or each mutant was added to each well
(50 Wl/well), and the plates were further incubated. Twenty-four hours
later, 10 Wl of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) solution (5 mg/ml) was added to each well and the
plates were further incubated for 4 h. Subsequently, 100 Wl of 10%
SDS in 0.01 M ammonium chloride was added to each well. The plate
was then incubated overnight at 37‡C to solubilize the cells. The
optical density at 590 nm of each well of the plates was measured.
3. Results
3.1. Identi¢cation of residues essential for the biological
function of dHGF by alanine scanning mutagenesis
Mutants were produced in which multiple or single charged
residue(s) in the N-terminal domain and the ¢rst kringle do-
main was/were replaced with alanine, and their mitogenic ac-
tivity was determined. The speci¢c activity of the mutants to
stimulate DNA synthesis in rat hepatocytes at a concentration
of 1.25 ng/ml is shown in Fig. 2A. The results are expressed as
activity relative to that of wild-type dHGF. Of the N-terminal
domain mutants, DKARK59AAAAA and ENKD89ANAA
were inactive. Next, mutants in which each of the charged
residues in 59DKARK and 89ENKD was replaced with ala-
nine (with an exception of RK62AA, where both 62R and
63K were replaced with alanine residues) were generated. As
shown in the left two columns in Fig. 2B, all six mutants
maintained the biological activity, suggesting that individual
residues are not functionally crucial. In contrast, none of the
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Fig. 1. Alignments of the amino acid sequences of human HGF and
dHGF (excluding the signal peptide). The amino acids are num-
bered starting at the amino-termini of the mature proteins. Positions
of alanine substitutions in dHGF mutants and their sequences after
mutagenesis are shown in the bottom row.
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mutations in the hairpin loop structure, D37A, R42A, R45A,
K47A and K54A, markedly a¡ected the biological activity
(Fig. 2A). The mutation at two sites in the ¢rst kringle do-
main, HEH127AAA and EVRYE159AVAYA, abolished the
biological activity. To determine the residues essential for the
activity, a single amino acid substitution was introduced into
these two ‘mutation-sensitive’ sites. As shown in the right two
columns in Fig. 2B, two mutants, E128A and R161A, were
inactive, indicating that the residues 128E and 161R are re-
quired for dHGF to exert its biological activity.
As shown in Fig. 2A, several mutants were found to be
more potent than dHGF in stimulating DNA synthesis in
rat hepatocytes. These mutants were puri¢ed to homogeneity
(purity was over 95%) and their biological activity was eval-
uated. In this second screening, two mutants, RKRR2AAAA
and KIKTKK27AIATAA, reproducibly showed increases in
speci¢c activity (see below) and were characterized further.
Mutants RKRR2AAAA and KIKTKK27AIATAA were re-
named #2 and #27, respectively.
3.2. Stimulation of DNA synthesis in adult rat hepatocytes by
puri¢ed mutants #2 and #27
Fig. 3 shows the ability of the two mutants to stimulate
DNA synthesis in cultured adult rat hepatocytes. In a dose
range of 1^16 ng/ml, the two mutants were signi¢cantly higher
in speci¢c activity than dHGF. The EC50 values for #2 and
#27 were approximately three-fold lower than that for dHGF.
The maximum stimulation levels for #2 and #27 were the
same as that for dHGF.
3.3. Biological activities of mutants #2 and #27 on NFS-60 and
OK cells
As shown in Fig. 4A, the two mutants were less potent than
dHGF in the stimulation of NFS-60 (a mouse bone marrow
cell line) cell proliferation in a dose range of 0.5 to 32 ng/ml.
Mutants #2 and #27 showed increases in EC50 by approxi-
mately three- and eight-fold, respectively, compared with
wild-type dHGF. Similarly, the ability of the mutants to stim-
ulate DNA synthesis in NFS-60 was lower than that of dHGF
in terms of EC50 (data not shown). As shown in Fig. 4B, the
two mutants were more potent than dHGF in the stimulation
FEBS 20733 27-8-98
Fig. 3. E¡ect of dHGF mutants, #2 or #27, on the stimulation
of DNA synthesis in rat hepatocytes. Cells were incubated with var-
ious concentrations of dHGF, mutants #2 (A) or #27 (B). A:
dHGF (E) and mutant #2 (a). B: dHGF (E) and mutant #27 (O).
Each value represents the mean þ S.D. of triplicate experiments.
Fig. 2. Biological activity of alanine substitution mutants relative to
dHGF. A: Biological activity of the alanine substitution dHGF mu-
tants relative to dHGF. Asterisks indicate lack of detectable activ-
ity. B: Relative biological activity of dHGF mutants with single or
double (62RK) substitution(s) in the four mutation-sensitive regions
identi¢ed by the experiment shown in A. Asterisks indicate lack of
detectable activity.
M. Kinosaki et al./FEBS Letters 434 (1998) 165^170 167
of DNA synthesis in OK cells. In the tested range of 1^64 ng/
ml, mutants #2 and #27 showed decreases in EC50 by approx-
imately 1.5- and three-fold, respectively, compared with wild-
type dHGF. However, the maximum response levels of the
two mutants on both NFS-60 and OK cells were comparable
to those of dHGF.
3.4. Amino-terminal sequences of mutants #2 and #27
Four positively charged residues are replaced with alanine
residues in mutants #2 and #27. These amino acid substitu-
tions may cause a conformational change that can eventually
expose a possible protease-sensitive site. Mutant #2 has a
predicted amino acid sequence of QAAAA in its N-terminus,
which is a possible substrate for the signal peptidase. To ex-
amine whether any protease digestion had occurred in the cell
or in the conditioned medium, the N-terminal amino acid
sequences of the two mutants were determined. The amino-
termini of the K chains of both mutants were blocked, as is
the case with dHGF. The amino acid residues from the second
to the ¢fth positions of #2 were AAAA, and those of #27
were RKRR. The amino-terminal sequences of the L chains of
both mutants were VVNGI. These results indicate that the
substitutions of amino acid residues did not induce the sus-
ceptibility to protease.
3.5. A⁄nity of mutants #2 and #27 to heparin
Conditioned medium of cells expressing #2 or #27 was
loaded on a HiTrap heparin column and the bound protein
was eluted with NaCl-containing bu¡er. As shown in Fig. 5,
the mutants #2 and #27 were eluted from the column at NaCl
concentrations of 0.78 M and 0.82 M, respectively, whereas
dHGF was eluted at that of 1.14 M.
4. Discussion
It has been reported that dHGF is distinguishable from
HGF in several ways. First, dHGF is more potent than
HGF in the stimulation of DNA synthesis in cultured adult
rat hepatocytes [10,22] and in epithelial cells [23]. Conversely,
HGF is more potent in the stimulation of DNA synthesis in
mesenchymal cells [23]. Second, dHGF is over 70-fold less
soluble than HGF in PBS [23]. Finally, several monoclonal
antibodies raised against dHGF do not recognize HGF or
2-mercaptoethanol-reduced dHGF [23], demonstrating that
the two forms of HGF are di¡erent in tertiary structure. In
the present study, to obtain further insight into the structure-
function relationships of HGF and dHGF, we analyzed
dHGF by alanine scanning mutagenesis.
Our analysis of mutants with alanine substitution(s) in the
N-terminal domain of dHGF has identi¢ed two sites impor-
tant for its biological activity. One of the sites, 59DKARK, is
in the hairpin loop structure. This suggests that the hairpin
loop structure of dHGF is a structurally or functionally im-
portant region, as is the case with HGF [22,34]. However, the
¢nding that the ¢ve other point mutations in the hairpin loop
structure, D37A, R42A, R45A, K47A and K54A, did not
a¡ect the biological activity (Fig. 2A) indicates that the integ-
rity of the structure is not crucial for the mitogenic activity.
The other mutant, ENKD89ANAA, which has no detectable
mitogenic activity on rat hepatocytes, has mutations in the
region between the hairpin loop structure and the ¢rst kringle
domain. Unexpectedly, none of the single point mutations in
59DKARK and 89ENKD abolished the biological activity
(Fig. 2B), suggesting that no speci¢c residue in the two
stretches is directly involved in the interaction with the recep-
tor. Lokker et al. demonstrated that the production levels of
HGF (not dHGF) mutants with mutations at the positions
corresponding to 59DKARK and 89ENKD (termed
D90A,K91A,R93A,K94A and E121A,N122A,K123A,D124A,
respectively in [28]) are low in human kidney 293 cells [28].
Taken together, these results suggest that the two regions may
be important for the folding of both HGF and dHGF into
proper structures.
A comparison of the results obtained from the mutational
study of dHGF (present study) and that of HGF [28] clari¢es
the similarities of and the di¡erences between the two forms
of HGF. An HGF mutant, K52A,D54A, had lower mitogenic
activity than did wild-type HGF on hepatocytes [28], while the
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Fig. 5. HiTrap heparin column chromatography of dHGF and
dHGF mutants #2 and #27. Conditioned medium of a cell line ex-
pressing dHGF (dotted line), dHGF mutants #2 (dot-dashed line)
or #27 (solid line) was loaded on a HiTrap heparin column as de-
scribed in Section 2.
Fig. 4. Mitogenic activity of dHGF mutants, #2 and #27, on (A)
NFS-60 (murine myeloblastic cells) or (B) OK (American opossum
kidney cells). Cells were incubated with various concentrations of
dHGF (E), mutant #2 (a) or mutant #27 (O). Each value repre-
sents the mean þ S.D. of the triplicate experiments.
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corresponding dHGF mutant (KID21AIA) had a speci¢c ac-
tivity comparable to that of wild-type dHGF (Fig. 2A). This
suggests that the role of the KID sequence in the biological
activity is di¡erent between HGF and dHGF. HGF mutants,
H114A,E115A,D117A and D171A, could not stimulate DNA
synthesis in rat hepatocytes, due to their inability to bind to
the receptor [28], whereas the corresponding dHGF mutants
(HEND83AANA and RGKD132AGAA, respectively) main-
tained the biological activity (Fig. 2A). These results strongly
suggest that the residues involved in the binding to the recep-
tor are di¡erent between dHGF and HGF. The mutational
analysis in the ¢rst kringle domain also identi¢ed two sites,
HEH127 and EVRYE159, as sequences essential for the bio-
logical function of dHGF. Our analysis of the mutants with a
single point mutation in these regions revealed that 128E and
161R are crucial for the biological function of dHGF. Sim-
ilarly, the alanine substitution of 128E and 166R of HGF,
residues that correspond to 128E and 161R of dHGF, respec-
tively, resulted in a loss of receptor binding capability [28].
Therefore, these may be the key residues for both HGF and
dHGF to exert the mitogenic activity on rat hepatocytes.
Two mutants (termed #2 and #27) had increased mitogenic
activity on rat hepatocytes and OK cells. Replacement of four
basic amino acid residues in the N-terminal region with ala-
nine residues resulted in a marked decrease in a⁄nity for
heparin (Fig. 5). All of the HGF mutants with no a⁄nity
for heparin lose the biological activity [24,34], suggesting
that binding to heparin is crucial for the biological function
of HGF. Naka et al. showed that cell surface heparin-like
molecules are important in the formation of the high-a⁄nity
binding sites for HGF [35]. The functional importance of
binding to heparin has been reported for other cytokines
[36]. However, our analysis of mutants #2 and #27 demon-
strated that an about 30% reduction in the heparin binding
capability does not diminish the biological activity of dHGF.
Further analysis of these two mutants will shed light on the
relationship between the heparin binding capability and the
biological activity of dHGF.
In some cytokines, mutations in the N-terminal region re-
sult in an increase in their biological activity. These include
human granulocyte colony-stimulating factor (G-CSF) [37^
39], mouse granulocyte-macrophage colony-stimulating factor
(GM-CSF) [40] and human tumor necrosis factor-K (TNF-K)
[41]. These examples demonstrated that an alteration of the
N-terminal region can increase the structural stability or af-
¢nity for their signaling receptors. Similar to these cytokines,
the mitogenic activity of dHGF on rat hepatocytes was in-
creased when four amino acid residues in the N-terminal re-
gion were replaced with alanine residues. Whether or not the
mutations in£uence the protein stability and/or a⁄nity for the
receptor is currently under study. It is also of great impor-
tance to examine the possibility that the reduction in heparin
binding capability is related to the increase in mitogenic ac-
tivity of the two mutants on rat hepatocytes and OK cells (but
not NFS-60).
A previous study has shown that dHGF is not as potent as
HGF in stimulating DNA synthesis in mesenchymal cells in-
cluding NFS-60. However, dHGF is more potent than HGF
in stimulating DNA synthesis in epithelial cells including OK
cells [23]. Such features of dHGF seemed to be maintained or
rather enhanced in mutants #2 and #27. The two mutants
may therefore have some advantage in the treatment of dis-
eases that involve epithelial cells in organs such as liver and
kidney. Indeed, preliminary in vivo experiments showed that
these two mutants are more potent than dHGF in the stim-
ulation of liver function as judged from protein synthesis (M.
Kinosaki et al., in preparation).
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